What GLP-1 biosimilars does Amogen manufacture?

Amogen manufactures semaglutide and liraglutide biosimilar APIs using Saccharomyces cerevisiae recombinant fermentation at Plant 1, Hyderabad. Semaglutide is currently in Phase 1 clinical development targeting Q4 2026 first patient.

What is Amogen Pharma's manufacturing capacity?

Amogen operates 980 Kg total GLP-1 fermentation capacity at Plant 1, Hyderabad — comprising five 15KL fermenters and two 1KL fermenters, making it one of the largest dedicated GLP-1 API facilities in India.

Which markets is Amogen open to partnering in?

Amogen is open to biosimilar API supply and licensing partnerships across India, GCC, ASEAN, Canada, selected Africa and CIS, selected LATAM, European Union and North America.

Why does Amogen use Saccharomyces cerevisiae instead of E. coli?

Amogen's S. cerevisiae expression system mirrors the innovator's host system used by Novo Nordisk, delivering salt-free APIs with correct higher-order structure and solubility at commercial scale above 1000 Kg — advantages that E. coli and synthetic SPPS routes cannot replicate.

What does Amogen provide to biosimilar partners?

Amogen provides drug substance API supply, drug product in pen or cartridge format, analytical packages for DS and DP, ICH-compliant pre-clinical toxicology reports, regulatory and market access support, and long-term volume-linked pricing with secured GLP-1 capacity.

High-barrier peptide and recombinant biosimilars, built for global partnership.

Amogen develops and manufactures recombinant peptide and protein biosimilars through innovator-aligned microbial expression platforms designed for scale, quality, and enduring global partnerships.

Amogen Pharma Plant 1 Hyderabad — India largest recombinant peptide API facility

Partner With Us View Pipeline >

BUILT FOR QUALITY AND SCALE

We manufacture with precision. Because the right molecule, made wrong, helps no one.

Amogen combines microbial expression expertise, fermentation scale, and process discipline to advance recombinant biosimilars from development to dependable long-term supply.

Amogen Pharma Plant 1 facility aerial view — Hyderabad recombinant biosimilar manufacturing

75,000L

Total Fermentation Capacity

S. cerevisiae and multi-microbial suites facility

75+

Scientific & Manufacturing Experts

84% in R&D and manufacturing functions, averaging 15 years of peptide expertise.

980+Kgs

GLP-1 API Produced

Current semaglutide output — expanding to meet global demand.

Amogen scientist conducting recombinant biosimilar research

10+

Active Development Programs

Across GLP-1 agonists, insulin analogues and immunology

OUR SCIENCE

Proprietary platforms, built to advance high-barrier recombinant biosimilars

Amogen scientist working in recombinant biosimilar research laboratory

Amogen's science is built on innovator-aligned microbial expression and manufacturing systems designed to deliver the purity, scalability, and process consistency required for complex recombinant biosimilars.

Proprietary Platforms

Proprietary microbial expression systems, led by YESTIDE™, our yeast-based platform engineered to support recombinant peptide and protein biosimilars across GLP-1, insulin, and immunology.

Manufacturing Systems

Advanced fermentation and downstream systems, led by CONTINEX™, our continuous manufacturing platform designed to deliver process consistency, scalable output, and dependable long-term supply.

Pipeline Translations

Platform science translated into active recombinant biosimilar programs across GLP-1, insulin, and immunology — creating structured pathways for development, licensing, and long-term supply partnerships.

A Pipeline Built on
Platform Advantage.

High-barrier recombinant biosimilars built on YESTIDE™, Amogen’s proprietary Saccharomyces cerevisiae expression platform — aligned with the innovator manufacturing process to deliver superior purity, scalability, and regulatory alignment that synthetic routes cannot replicate.

View Full Pipeline →

Program

DevelopmentAnalytical CMCPre-Clinical

Next Milestone

Semaglutide Biosimilar

Phase 1

Liraglutide Biosimilar

Pre-Clinical

INSULIN ANALOGS

Insulin Degludec Biosimilar

Pre-Clinical

Insulin Aspart Biosimilar

Pre-Clinical

IMMUNOLOGY

Certolizumab Biosimilar

Pre-Clinical

Anakinra Biosimilar

Analytical CMC

View Full Pipeline →

OUR CAPABILITIES

One facility, Multi-microbial platforms,
Integrated Execution.

From expression and fermentation through downstream processing and analytical development, Amogen brings the core capabilities required to advance recombinant biosimilars from development to dependable supply.

Explore our CDMO services →

API MANUFACTURING